Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Cell Host Microbe. 2013 Mar 13;13(3):250-62. doi: 10.1016/j.chom.2013.02.009.
There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.
目前迫切需要新的、更好的结核病（TB）疫苗。当前的疫苗设计策略通常侧重于增强细胞介导的免疫。抗体方法未被考虑，主要是因为这种范式，即体液免疫在针对细胞内病原体的保护中作用不大。在这里，我们重新评估和更新越来越多的针对结核分枝杆菌的抗体介导免疫的证据，讨论针对分枝杆菌的抗体反应的复杂性，并解决保护机制。基于这些发现和讨论，我们挑战了一种普遍的信念，即对 M. tuberculosis 的免疫仅依赖于细胞防御机制，并假设诱导抗体介导的免疫应包括在结核病疫苗开发策略中。
